ISSOIRE, France--(BUSINESS WIRE)--Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, and VARI, a subsidiary of LINDAL GROUP manufacturing valves and actuators for pharmaceutical aerosol systems, announce that they have reached a commercialization agreement.
This partnership will enable VARI to integrate and commercialize InspairTM. The contract includes an exclusivity clause covering several countries in South America, Eastern Europe, Middle East and Southeast Asia.
Designed and developed by BIOCORP, Inspair is a smart sensor converting inhalers into connected devices to help patients with asthma or chronic obstructive pulmonary diseases (COPD).
Inspair brings an innovative and effective response to the needs of these two pathologies: it acts directly on the treatment compliance and strengthens the connection between the patient and the medical staff, providing a real-time therapeutic follow-up. This smart sensor converts any pressurized metered dose inhaler into a connected device. Inspair records data related to daily inhalations, ensures the right preparation of the canister, assesses the coordination of actuation with inhalation and provides a useful guidance throughout different steps, mastering the inhalation technique.
“Chronic lung diseases affect an increasing number of people who need solutions to improve compliance. Signing this contract is a step forward in the field of connected health. LINDAL is a major player in the market and this partnership is a significative opportunity for providing connectivity features to the end patient and help him to better manage his treatment “, underlines Eric Dessertenne, COO of BIOCORP.
“This partnership with BIOCORP will enhance LINDAL product portfolio with a highly innovative offering in a context where connected health is getting more and more popular. Patients are very keen on collecting their health data to actively manage their therapy by sharing it with their doctor. This technology is particularly interesting for people with chronic diseases, like asthma or COPD, helping them to easily and accurately adjust their treatment “, declared Sergio Monti, VARI Sales Director.
ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand),
France, BIOCORP is a French company specializing in the development and
manufacturing of medical devices and innovative drug delivery systems.
It is listed as ‘Innovative Company’ by the French public investment
bank Bpifrance. With over twenty years of experience and more than 30
manufactured products, BIOCORP is a key player in the industry,
providing drug delivery solutions that meet the evolving needs of
patients. Today, BIOCORP continues to innovate in medical plastics, its
core business, and to market traditional devices (alternative to
aluminum capsules, syringe and vial administration systems) that have
been an important source of recurring income. Its solid expertise and
capacity to innovate have allowed the company to develop new
Internet-connected products, including Easylog, a smart cap for pen
injectors that captures injection data and automatically transmits data
to a mobile app, helping patients to manage their treatment. The company
has a team of 47 employees. BIOCORP is listed on Alternext since July
2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
Follow
us on Twitter @BIOCORPSystems
ABOUT LINDAL GROUP
LINDAL Group was founded in 1959 and today is
one of the world’s market leaders in aerosol packaging technology.
LINDAL Group offers a broad range of standard and custom aerosol
packaging solutions and has become a partner of choice for many of the
world’s most prestigious, innovative and trusted brands. LINDAL products
include standard and specialized valve and actuator technologies. The
company serves customers in personal care, homecare, pharmaceuticals,
food and technical segments.
For more information, please visit www.lindalgroup.com
